GIGABYTE
24.6.2021 12:47:12 CEST | Business Wire | Press release
GIGABYTE, a world leader in computer technology, is excited to be part of MWC (Mobile World Congress) to present its products and insights on Edge computing , and be joined by innovators and decision-makers who will shape the future of 5G deployments and 6G planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005477/en/
GIGABYTE presents a series of servers that are “short and sweet”, and available in either x86 or Arm platforms to support diverse applications. Not only are these Edge servers shortened to depths ranging from only 400-600mm to fit in more environments for telecom deployments, but also ready to serve as HPCs to handle challenging workloads for AI and data processing that are closer to users’ applications.
- E152-ZE0 - Supports 3rd Gen AMD EPYC 7003 and 7002 processors, is extremely short with 400mm in depth, comes with 8 DIMM slots, and supports two U.2 NVMe SSDs. The E152 chamber for dual-slot GPUs can also be used for two single-slot cards operating at Gen4 x16, and two low-profile expansion slots on the front to provide user with powerful performance and flexibility for implementation.
- E162-220 - Designed for 3rd Gen Intel Xeon Scalable processors and has 16 DIMMs for industry standard 8-channel memory, and supports two U.2 SSDs and three M.2 connectors onboard with Gen4 PCIe transmission. All I/Os are designed in the same direction, making it suitable not only for installation in data centers, but also for deployment in base stations to provide 5G MEC or edge computing for services.
- E251-U70 - The first GIGABYTE edge server designed for 2nd Gen Intel Xeon Scalable processors, supporting six 2.5” SATA/SAS bays on the front-left, and a dual-slot GPU plus a FHFL single-slot card on the front-right. Notably, this server was chosen by NVIDIA Aerial Developer Kit for development and deployment of vRAN stack. E251-U71, a SKU variant that is NEBS design ready, is designed for extreme conditions such as high temperature, humidity or altitude.
- E252-P30 – Built for workloads on Arm architecture and uses Ampere Altra processors with up to 80 cores and 16 DIMMS for a wealth of possibilities in the cloud, the server is a viable option when considering TCO. It has six SSDs bays and lots of expansion slots for low-profile accelerators, storage, or networking.
The “short”ness of GIGABYTE Edge servers’ chassis and the “sweet”ness of its performance capabilities will prove to be indispensable equity in telecommunications, as the success in 5G deployments demands a widespread of MEC networks that are both closely-and-intelligently-connected.
GIGABYTE is an engineer, visionary, and leader in the tech world that uses its hardware expertise, patented innovations, and industry leadership to create, inspire, and advance. With over 30 years of celebrated experience, GIGABYTE is pleased to be the backbone of the IT infrastructure and provide the industry with data center expertise and cutting-edge server products that can accelerate scientific and technological breakthroughs.
https://www.mwcbarcelona.com/exhibitors/gigabyte-technology
See more presentations: https://www.gigabyte.com/Tech-Tune-In
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005477/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
